Published in Apoptosis on July 01, 2007
Differential regulation of the apoptotic machinery during megakaryocyte differentiation and platelet production by inhibitor of apoptosis protein Livin. Cell Death Dis (2013) 0.77
Birc7: A Late Fiber Gene of the Crystalline Lens. Invest Ophthalmol Vis Sci (2015) 0.76
Livin/BIRC7 expression as malignancy marker in adrenocortical tumors. Oncotarget (2016) 0.75
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med (2006) 6.54
Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. Immunity (2008) 6.49
Host immune system gene targeting by a viral miRNA. Science (2007) 5.10
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med (2014) 5.08
Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat Immunol (2006) 5.00
Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood (2010) 3.99
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe (2009) 3.59
Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat Immunol (2008) 3.14
Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol (2012) 2.65
Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol (2005) 2.55
Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci U S A (2002) 2.53
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol (2008) 2.45
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol (2009) 2.32
Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. Stem Cells (2005) 2.24
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol (2012) 2.13
The mechanisms controlling the recognition of tumor- and virus-infected cells by NKp46. Blood (2003) 2.06
Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica (2007) 1.95
CD11cloB220+ interferon-producing killer dendritic cells are activated natural killer cells. J Exp Med (2007) 1.82
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A (2009) 1.77
NKp46-mediated killing of human and mouse hepatic stellate cells attenuates liver fibrosis. Gut (2011) 1.75
Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol (2013) 1.70
Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR. Eur J Immunol (2013) 1.65
CXCL12 expression by invasive trophoblasts induces the specific migration of CD16- human natural killer cells. Blood (2003) 1.62
Retracted Novel APC-like properties of human NK cells directly regulate T cell activation. J Clin Invest (2004) 1.58
Novel insights on human NK cells' immunological modalities revealed by gene expression profiling. J Immunol (2004) 1.57
The activating receptor NKp46 is essential for the development of type 1 diabetes. Nat Immunol (2009) 1.54
The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol (2004) 1.53
NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med (2012) 1.52
The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study. J Urol (2007) 1.50
The human cytomegalovirus microRNA miR-UL112 acts synergistically with a cellular microRNA to escape immune elimination. Nat Immunol (2010) 1.48
Tumor and viral recognition by natural killer cells receptors. Semin Cancer Biol (2006) 1.48
Harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy. PLoS One (2008) 1.47
The unique properties of uterine NK cells. Am J Reprod Immunol (2010) 1.46
The natural cytotoxicity receptor NKp46 is dispensable for IL-22-mediated innate intestinal immune defense against Citrobacter rodentium. J Immunol (2009) 1.44
Enhanced in vivo growth of lymphoma tumors in the absence of the NK-activating receptor NKp46/NCR1. J Immunol (2009) 1.44
Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia. Leuk Lymphoma (2014) 1.42
CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. J Immunol (2002) 1.34
Enhanced recognition of human NK receptors after influenza virus infection. J Immunol (2003) 1.29
An identical miRNA of the human JC and BK polyoma viruses targets the stress-induced ligand ULBP3 to escape immune elimination. Cell Host Microbe (2011) 1.28
Caspase-mediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor: implications for drug-resistant melanoma. Cancer Res (2003) 1.25
MiR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells. Cancer Res (2012) 1.23
Complexes of HLA-G protein on the cell surface are important for leukocyte Ig-like receptor-1 function. J Immunol (2003) 1.23
An integrated view of the regulation of NKG2D ligands. Immunology (2009) 1.23
Analysis of human cytomegalovirus-encoded microRNA activity during infection. J Virol (2009) 1.22
MHC class I-independent recognition of NK-activating receptor KIR2DS4. J Immunol (2004) 1.22
Direct recognition of Fusobacterium nucleatum by the NK cell natural cytotoxicity receptor NKp46 aggravates periodontal disease. PLoS Pathog (2012) 1.22
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol (2007) 1.21
The CD85J/leukocyte inhibitory receptor-1 distinguishes between conformed and beta 2-microglobulin-free HLA-G molecules. J Immunol (2005) 1.21
Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus. Eur J Immunol (2004) 1.20
Recruitment of MHC class I molecules by tapasin into the transporter associated with antigen processing-associated complex is essential for optimal peptide loading. J Immunol (2002) 1.18
Endometrial NK cells are special immature cells that await pregnancy. J Immunol (2008) 1.18
Tumor immunoediting by NKp46. J Immunol (2010) 1.18
The NKp46 receptor contributes to NK cell lysis of mononuclear phagocytes infected with an intracellular bacterium. J Immunol (2002) 1.17
Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions. J Clin Invest (2002) 1.14
Influenza virus infection augments NK cell inhibition through reorganization of major histocompatibility complex class I proteins. J Virol (2008) 1.14
Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice. Blood (2003) 1.13
Role of promoter methylation in regulation of the mammalian heparanase gene. Oncogene (2003) 1.12
Altered glycosylation of recombinant NKp30 hampers binding to heparan sulfate: a lesson for the use of recombinant immunoreceptors as an immunological tool. Glycobiology (2007) 1.12
A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol (2014) 1.11
Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1. J Immunol (2005) 1.11
Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules. J Immunol (2013) 1.11
Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies. PLoS Genet (2013) 1.10
When killers become helpers. Trends Immunol (2007) 1.09
Recognition and prevention of tumor metastasis by the NK receptor NKp46/NCR1. J Immunol (2012) 1.09
MiRNA-mediated control of HLA-G expression and function. PLoS One (2012) 1.08
H5-type influenza virus hemagglutinin is functionally recognized by the natural killer-activating receptor NKp44. J Virol (2007) 1.08
Functional aberrant expression of CCR2 receptor on chronically activated NK cells in patients with TAP-2 deficiency. Blood (2005) 1.07
Expression of KIR2DL1 on the entire NK cell population: a possible novel immunodeficiency syndrome. Blood (2004) 1.07
Virus-mediated inhibition of natural cytotoxicity receptor recognition. Cell Mol Life Sci (2012) 1.06
Expression and function of CD300 in NK cells. J Immunol (2010) 1.06
Dynamic behavior of NK cells during activation in lymph nodes. Blood (2009) 1.04
Neisserial outer membrane vesicles bind the coinhibitory receptor carcinoembryonic antigen-related cellular adhesion molecule 1 and suppress CD4+ T lymphocyte function. Infect Immun (2007) 1.03
Killing of avian and Swine influenza virus by natural killer cells. J Virol (2010) 1.03
Therapy-related leukemia and myelodysplasia: evolving concepts of pathogenesis and treatment. Hematology (2004) 1.02
Recognition and killing of human and murine pancreatic beta cells by the NK receptor NKp46. J Immunol (2011) 1.01
The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients. Blood (2003) 1.00
Clinical implications of acute myeloid leukemia presenting as myeloid sarcoma. Hematol Oncol (2011) 1.00
Intracellular cysteine residues in the tail of MHC class I proteins are crucial for extracellular recognition by leukocyte Ig-like receptor 1. J Immunol (2007) 1.00
Paired NK cell receptors controlling NK cytotoxicity. FEBS Lett (2010) 1.00
CEACAM1 (CD66a) promotes human monocyte survival via a phosphatidylinositol 3-kinase- and AKT-dependent pathway. J Biol Chem (2006) 0.99
Inhibitory NK receptor recognition of HLA-G: regulation by contact residues and by cell specific expression at the fetal-maternal interface. PLoS One (2010) 0.96
Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions. J Immunol (2006) 0.95
Elucidating the mechanisms of influenza virus recognition by Ncr1. PLoS One (2012) 0.94
Immune evasion by oncogenic proteins of acute myeloid leukemia. Blood (2014) 0.94
Expression of ligands to NKp46 in benign and malignant melanocytes. J Invest Dermatol (2007) 0.93
The natural cytotoxicity receptor 1 contribution to early clearance of Streptococcus pneumoniae and to natural killer-macrophage cross talk. PLoS One (2011) 0.92
The critical role of residues 43R and 44Q of carcinoembryonic antigen cell adhesion molecules-1 in the protection from killing by human NK cells. J Immunol (2004) 0.92
NKp46 O-glycan sequences that are involved in the interaction with hemagglutinin type 1 of influenza virus. J Virol (2010) 0.91
Soluble nonclassical HLA generated by the metalloproteinase pathway. Hum Immunol (2003) 0.91
CEACAM1 dampens antitumor immunity by down-regulating NKG2D ligand expression on tumor cells. J Exp Med (2011) 0.88
Ethnicity and prognosis in acute myeloid leukemia. Am J Hematol (2003) 0.87
The interaction between CD300a and phosphatidylserine inhibits tumor cell killing by NK cells. Eur J Immunol (2013) 0.86
The clinical effect of the inhibitor of apopotosis protein livin in melanoma. Oncology (2012) 0.86
Imaging-guided percutaneous splenic biopsy using a 20- or 22-gauge cutting-edge core biopsy needle for the diagnosis of malignant lymphoma. AJR Am J Roentgenol (2003) 0.86